匹多莫德联合常规治疗措施治疗反复呼吸道感染患儿疗效及免疫调节作用观察

Efficacy and Immunoregulation of Pidotimod Combined with Routine Therapy in Children with Recurrent Respiratory Tract Infections

目的：研究匹多莫德联合常规治疗措施治疗反复呼吸道感染患儿的疗效及对免疫调节的作用。方法：反复呼吸道感染患儿114例按入院先后顺序分为两组。对照组58例采用常规治疗，观察组56例在对照组基础上加用匹多莫德。治疗2个月后，对全部患儿随访1~6个月，观察两组患儿症状体征消失时间、临床疗效、复发情况及各项生理指标，比较两组患儿免疫功能变化。结果：观察组临床症状与肺部体征消失时间明显短于对照组（P〈0.05）；总有效率为92.86%，明显高于对照组的67.24%（P〈0.001）。观察组患儿上、下呼吸道感染次数明显低于对照组（P〈0.05）。治疗后，观察组患儿各项免疫指标均有明显提高（P〈0.01），且明显高于对照组（P〈0.05或0.01）；而对照组患儿治疗前后免疫指标比较，差异无统计学意义（P〉0.05）。结论：反复呼吸道感染患儿应用匹多莫德联合常规治疗措施治疗的疗效良好，且能够有效提高患儿的免疫能力。

Objective：To study the efficacy and immunoregulation of pidotimod combined with routine treatment in the children with recurrent respiratory tract infections. Methods：Totally 114 cases of children with recurrent respiratory tract infections were divid-ed into the control group and the treatment group according to the sequence of hospitalization. The 58 patients in the control group re-ceived the conventional treatment, while the 56 patients in the treatment group were given pidotimod additionally. After two-month treatment, all the children were given 1 -6-month follow-up, and the symptom disappearance time, clinical efficacy, recurrence, physiological indices and change of immunological function in the two groups were observed and compared. Results：The disappearance time of symptom and lung physical signs in the observation group was much shorter than that in the control group （P〈0. 05）;the total effective rate of the observation group was 92. 86%, which was significantly higher than that of the control group （67. 24%, P 〈0. 001）. The number of upper and lower respiratory tract infections in the observation group was significantly lower than that in the con-trol group （P〈0. 05）. After the treatment, the immune parameters in the observation group were significantly improved （P〈0. 01）, which were significantly higher than those in the control group （P〈0. 05 or P〈0. 01）. The immune parameters before and after the treatment in the control group showed no statistically significant difference （P〉0. 05）. Conclusion：Pidotimod combined with routine treatment in the children with recurrent respiratory tract infections exhibits promising efficacy, which can improve immunity effectively.